Ashley Duke
Family · Tallahassee, FLNPI 1467894279
Payments from drug & device makers
Across 203 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$664
- Boehringer Ingelheim$624
- AstraZeneca$515
- Lilly USA, LLC$355
- Pfizer$346
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$138
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,756100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $664 |
| Boehringer Ingelheim | 30 | $624 |
| AstraZeneca | 20 | $515 |
| Lilly USA, LLC | 30 | $355 |
| Pfizer | 20 | $346 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $138 |
| Dexcom, Inc. | 5 | $137 |
| Sanofi-aventis U.S. LLC | 5 | $115 |
| Exact Sciences | 6 | $106 |
| Phathom Pharmaceuticals, Inc. | 6 | $102 |
| Bayer | 5 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $82 |
| GSK | 5 | $72 |
| Astellas Pharma US Inc | 3 | $63 |
| AbbVie | 4 | $62 |
| Merck | 4 | $61 |
| Sanofi Pasteur Inc. | 3 | $59 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $27 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $15 |
| Smith+Nephew | 1 | $15 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,766 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 93 | $125,723 |
| FarxigaDapagliflozin Propanediol | 121 | $102,074 |
| MounjaroTirzepatide | 88 | $95,720 |
| JanuviaSitagliptin Phosphate | 48 | $57,318 |
| EliquisApixaban | 25 | $32,539 |
| JardianceEmpagliflozin | 25 | $28,264 |
| RybelsusSemaglutide | 22 | $24,585 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $21,823 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $18,953 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $16,341 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $10,039 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $7,566 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $7,009 |
| MyrbetriqMirabegron | 12 | $6,180 |
| Atorvastatin Calcium | 259 | $2,563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $664 | $150,308115 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $515 | $131,462178 claims |
| Lilly USA, LLCMounjaro | $355 | $95,72088 claims |
| MerckJanuvia | $61 | $57,31848 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $624 | $35,27338 claims |
| PfizerEliquis | $346 | $32,53925 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $115 | $16,34118 claims |
| GSKTrelegy Ellipta | $72 | $10,03915 claims |
| Astellas Pharma US IncMyrbetriq | $63 | $6,18012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Tallahassee
- Kathleen WilsonTallahassee$154K
- Brittany YatesTallahassee$73K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.